Sedor Pharmaceuticals
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1800 Lancaster Ave Ste N, Paoli, Pennsyl...Phone Number
(610) 455-2180Website
www.sedorpharmaceuticals.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Sedor Pharmaceuticals
Sedor Pharmaceuticals, LLC identifies, acquires and develops acute care pharmaceutical assets for commercial licensing. The Company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals, all possessing a proven track record of building pharmaceutical companies and creating shareholder value. The company's lead product, SESQUIENT, has received FDA approval for the treatment of status epilepticus. The company is preparing to enter Phase I development of its second product, Meloxicam for injection solubilized with betadex sulfobutyl ether sodium, for the potential treatment of acute post-surgical pain. If approved, it could possibly replace or delay the use of IM/IV opioids. Both products were licensed from Ligand Pharmaceuticals.Explore more
Sedor Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sedor Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Sedor Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Sedor Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sedor Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Sedor Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Sedor Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Sedor Pharmaceuticals
Earning: See what the market has to say on Sedor Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Sedor Pharmaceuticals is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Sedor Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Sedor Pharmaceuticals
Compare insights from companies similar to Sedor Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sedor Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sedor Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sedor Pharmaceuticals.
Sedor Pharmaceuticals Tech Stack
A closer look at the technologies used by Sedor Pharmaceuticals
Sedor Pharmaceuticals News & Media
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled™ Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients. Ready-to-dilute and room temperature stable, SESQUIENT is the only FDA-approved fosphenytoin that allows point-of-care storage, as wSedor Pharmaceuticals NDA for CE-Fosphenytoin for Status Epilepticus Receives PDUFA Date
Potential significant advance for life threatening condition Potential significant advance for life threatening condition
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sedor Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sedor Pharmaceuticals, LLC identifies, acquires and develops acute care pharmaceutical assets for commercial licensing. The Company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals, all possessing a proven track record of building pharmaceutical companies and creating shareholder value. The company's lea... Read More
